logo_graytitle
title

Contents

RSS Twitter YouTube Facebook

Partnerships in Health Care

Partnerships with Optum Labs and the Icahn School of Medicine at Mount Sinai are driving discoveries and innovations in health care at Rensselaer.

Partnership With Optum Labs
Rensselaer has joined as a charter partner of Optum Labs, the collaborative research and innovation center founded by Optum and Mayo Clinic committed to improving the quality and value of patient care.

Optum Labs

As a partner of Optum Labs, Rensselaer has access to information resources, proprietary analytical tools, and scientific expertise to help drive the discovery of new applications, testing of new care pathways, and other opportunities to drive innovation in wellness and care delivery.

“Rensselaer Polytechnic Institute is globally transforming biomedical research through the intersection of data science/analytics with biological sciences/bioengineering,” said Jonathan Dordick, Ph.D., vice president for research at Rensselaer. “Working with Optum Labs and the other partners, Rensselaer will forge a path from fundamental science to technology development that will result in innovation and discovery. The results of this new partnership will enable health care organizations to make better decisions, make better products, and ultimately, reduce costs of health care delivery.”

“Rensselaer Polytechnic Institute is globally transforming biomedical research through the intersection of data science/analytics with biological sciences/bioengineering. Working with Optum Labs and the other partners, Rensselaer will forge a path from fundamental science to technology development that will result in innovation and discovery.” —Jonathan Dordick

“The collaboration between our diverse group of partners will help Optum Labs accelerate the pace of innovation, paving the way for exciting new research initiatives that can be directly translated to improvements in patient care,” said Paul Bleicher, M.D., Ph.D., CEO of Optum Labs, and a member of the Rensselaer Class of 1976.

Optum Labs brings together a community of health care stakeholders dedicated to improving patient care by sharing information assets, technologies, knowledge, tools, and scientific expertise. Research is linked to the clinical environment through prototyping and testing in Optum and partners’ care settings, with a goal of achieving knowledge that improves health care delivery and patient outcomes.

Dordick said the partnership with Optum Labs provides a significant opportunity to help advance fundamental and translational research taking place at Rensselaer in the areas of drug discovery, human toxicology, and improved patient outcomes on a personalized basis. Other areas of interest include drug repurposing, health care analytics, clinical outcomes predictions, and novel target identification. The partnership with Optum Labs brings together two major research platforms at Rensselaer, the Center for Biotechnology and Interdisciplinary Studies (CBIS) and the Institute for Data Exploration and Applications (the Rensselaer IDEA).

Affiliation Agreement With Icahn School of Medicine at Mount Sinai
An affiliation agreement between the Icahn School of Medicine at Mount Sinai and Rensselaer in May 2013 enables collaboration on educational programs, research, and development of new diagnostic tools and treatments that promote human health.

Mount Sinai

The institutions launched the initiative to use their expertise—engineering and invention prototyping at Rensselaer and biomedical research and patient care at Mount Sinai—to provide synergy in their promotion of human health. Rensselaer and the Icahn School of Medicine are developing complementary research programs in neuroscience and neurological diseases, genomics, imaging, orthopaedics, cancer, cardiovascular disease, and scientific and clinical targets that capitalize on each institution’s unique strengths. Joint funding in research programs is being sought in the areas of  precision medicine, drug discovery, stem cell biology, robotics and robotic surgery, novel imaging techniques, cellular engineering, and computational neurobiology.

Initially, the key areas of focus are genomics, imaging, tissue engineering, and neuroscience. With the Icahn School of Medicine’s $3 million investment to build the Minerva supercomputer and the Rensselaer high-performance computing center at the the Center for Computational Innovations — featuring a new IBM Blue Gene/Q supercomputing system — the two institutions will implement some of the most advanced high-performance supercomputing in the world. This will enable them to quickly and efficiently produce sophisticated computer algorithms that analyze genomic data and develop predictive models of disease, which can better help diagnose and treat patients. Mount Sinai’s newly opened Hess Center for Science and Medicine and the Rensselaer Center for Biotechnology and Interdisciplinary Studies (CBIS) will serve as hubs for research and development.

This agreement was enhanced by the creation of the Mount Sinai Institute of Technology (MSIT), part of a $100 million public-private initiative to boost biotechnology innovation in New York. MSIT aims to educate a new generation of experts and create new technologies to help address and solve the world’s most critical health-care challenges.

Additionally, 8 joint research projects have been seeded by the partnership.

Rensselaer Icahn Affiliation Announcement

Rensselaer MSIT Announcement

Initial Rensselaer-Icahn School of Medicine at Mount Sinai Seed Funding